Table 5.
Multivariate analysis of prognostic factors for the whole cohort of patients with nasopharyngeal carcinoma (n = 334)
| HR (95% CI) | P‐value* | |
|---|---|---|
| Progression‐free survival | ||
| Smoking, no versus yes | 1.71 (1.00–2.95) | 0.052 |
| N stage, N0–1 vs N2–3 | 2.18 (1.22–3.89) | 0.008 |
| VCA‐IgA, <1:120 vs ≥1:120 | 1.52 (0.80–2.89) | 0.205 |
| Overall survival | ||
| Smoking, no versus yes | 2.62 (1.23–5.61) | 0.013 |
| N stage, N0–1 vs N2–3 | 2.90 (1.36–6.20) | 0.006 |
| Distant metastasis‐free survival | ||
| Smoking, no versus yes | 1.77 (0.86–3.64) | 0.119 |
| N stage, N0–1 vs N2–3 | 2.16 (1.31–4.67) | 0.031 |
| VCA‐IgA, <1:120 vs ≥1:120 | 1.77 (0.73–4.31) | 0.208 |
| Locoregional relapse‐free survival | ||
| Histology, WHO II vs III | 0.37 (0.13–1.08) | 0.070 |
| N stage, N0–1 vs N2–3 | 1.51 (0.68–3.34) | 0.309 |
| VCA‐IgA, <1:120 vs ≥1:120 | 2.45 (0.78–7.68) | 0.125 |
| EA‐IgA, <1:15 vs ≥1:15 | 1.05 (0.42–2.63) | 0.920 |
*P‐values were calculated with an adjusted Cox proportional hazards model. CI, confidence interval; EA‐IgA, IgA antibodies against early antigen; HR, hazard ratio; VCA‐IgA, IgA antibodies against viral capsid antigen.